Anivance ai

NO ANIMAL
NO HUMAN
JUST TECHNOLOGY

From Design to Delivery

The Fastest AI-powered Organ-on-chip solution

FDA

Aligned with FDA's 2025
Alternative Testing Roadmap

Anivance ai

WHERE BIOLOGY MEETS ENGINEERING: THE FUTURE OF IN VITRO MODELING

DRIVEN BY Taiwan's Semiconductor BUILD ORGANS AT SPEED

Biomimetic Organ-on-Chip Platform

- Validated in **10+ patient-derived** organ models, including airway, liver, intestine, and cancer.
- Supports **10+ biological indicators**, such as barrier integrity, mucus production, inflammatory response, and drug-induced toxicity.

Dynamic Perfusion System for Physiological Simulation

- Maintains dynamic culture with programmable flow and physiological shear stress.
- Supports cell differentiation and sustained functionality **across the 1–28 day culture** period.

Aerosol Exposure Module for Inhalation

- Automates 8-chip culture with **air, liquid, and aerosol delivery under air-liquid conditions**.
- Enables inhalation studies on drug deposition, ciliary motion, mucus clearance, and particle behavior for respiratory therapy testing.

 |

Technology Integration Platform

The Fastest Path From Organ Modeling To Toxicology Decisions



Multi-organ type validation

- Pulmonary fibrosis
- Pulmonary edema
- Alveolar surfactant deficiency
- Asthma
- Bronchogenic sepsis



- Gastric cancer
- Colorectal cancer
- Colon cancer
- Papillary thyroid carcinoma
- Breast cancer
- CTC

Powering the Fastest Toxicity Profiling



By leveraging our extensive library of organ models, we enables **early toxicity detection** within just 6 hours— **faster** than traditional method.

 |

Anivance ai

Unlocking Clinical Insights

An AI agent built for organ-on-chip platforms, streamlining the path from design to clinical decisions

Concentration-Response Relationship

Figure 1: The relationship between different concentrations of Survanta and the measured %Area of SP-B.



Effect of Nebulized Survanta on SP-B Distribution in A549 Cells

The effect of nebulized Survanta on SP-B distribution in A549 cells was assessed by measuring the percentage area of SP-B immunofluorescence. As shown in Table 1, contro cells exhibited a baseline SP-B distribution of 17.20 ± 2.17% area. Treatment with nebuli Survanta at 3.125 mg/ml resulted in a slight decrease in SP-B distribution to 15.66 ± 2.5 area, although this change was not statistically significant compared to control ($p > 0.05$)

Table 1: Percentage Area of SP-B Fluorescence in A549 Cells Treated with Different Concentrations of Nebulized Survanta

Doctor

Preclinical to Clinical Transition

Safety | Toxicity

Speciality: preclinical simulation and AI based clinical translation

Our Global Ecosystem

Accelerating Every Stage of Drug Development

NARLabs 國家實驗研究院 National Applied Research Laboratories
TSRI NARLabs 國家實驗研究院 台灣半導體研究中心 Taiwan Semiconductor Research Institute
DARWIN
LARGAN
臺中榮民總醫院 Taichung Veterans General Hospital
秀傳醫療體系 Show Chwan Healthcare System
馬偕紀念醫院 Mackay Memorial Hospital
國防醫學院 NATIONAL DEFENSE MEDICAL CENTER
台大醫院 NTUH
長庚紀念醫院 Chang Gung Memorial Hospital
天主教永和耕莘醫院 Yonghe Cardinal Tien Hospital
Cellentia
tlc 台灣微脂體
MOLECULAR DEVICES
PHISON
比翼生醫創投 BE HEALTH VENTURES
MiiS
NAIP 北美智權 North America Intellectual Property Co.

CONTACT US

Phone: +886 3 6126 258
Web: www.anivance.io
Email: info@anivance.io

Regional Offices

Taiwan / Headquarters: Rm. 6, 2F., No. 150, Sec. 2, Shengyi Rd., Zhubei City, Hsinchu County 302058, Taiwan.
Check our website for a current listing of worldwide distributors.

Anivance AI's platform supports the transition from discovery to regulatory submission, enabling human-relevant preclinical evaluation aligned with IND/CMC and FDA's New Approach Methodologies (NAMs).

Anivance ai